Tag

AC Immune SA

1 article

AC Immune Stock Gains 3.9% on Phase 1

AC Immune SA shares rose 3.9% in pre‑market trading after releasing preliminary Phase 1 data for its oral NLRP3 inhibitor ACI‑19764. The trial in healthy European volunteers showed the drug was safe,